SHANGHAI, CHINA and MELBOURNE, AUSTRALIA — September 28, 2020 — Antengene Corporation, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, announced today that it has dosed the first patient in a Phase I clinical trial in Australia with ATG-017，a potent and selective small molecule extracellular signal–regulated kinases 1 and 2 (ERK1/2) inhibitor，for the treatment of advanced solid tumors and hematological malignancies (ERASER trial). This trial aims to investigate the safety and preliminary efficacy of ATG-017 monotherapy.
Aberrations in the MAPK pathway are amongst the most common in solid tumors and are closely associated with a range of largely incurable hematological malignancies. As a potent oral and selective small molecule ERK1/2 inhibitor, ATG-017 acts on the terminal protein of RAS-RAF-MEK-ERK signaling pathway and inhibits the viability of tumor cell lines in-vitro as well as tumor growth in-vivo.
“The RAS/MAPK pathway is a major driving factor of oncogenesis. ATG-017 targeting ERK1/2 is being developed to inhibit the growth of tumor cells and combine with other MAPK kinase inhibitors to more effectively block the RAS-MAPK signaling and overcome the resistance to RAF and MEK inhibitors.” said Dr. Jay Mei, Founder, Chairman and CEO of Antengene, “We believe ATG-017 has great clinical potential and prospects for broad applications as a monotherapy in solid tumors and hematological malignancies and in combination with other Antengene pipeline assets. We will be conducting further studies to explore potential synergies and achieve better treatment outcomes.”
ATG-017 is a potent and selective small molecule extracellular signal–regulated kinases 1 and 2 (ERK1/2) inhibitor. Antengene has obtained the exclusive global rights to develop, manufacture and commercialize ATG-017. At present, Antengene is conducting a Phase I clinical trial of ATG-017 for the treatment of advanced solid tumors and hematological malignancies in Australia, including non-Hodgkin’s lymphoma.
Antengene is a biopharmaceutical company with integrated drug discovery, clinical development, manufacturing and commercialization, anchored in Asia Pacific with a global layout. Antengene aims to provide the most advanced anti-cancer drugs to patients in China, the rest of Asia Pacific and around the world. Since official operation in April 2017, Antengene has built a pipeline of 12 clinical and pre-clinical stage assets, obtained 9 IND approvals and has 9 ongoing cross-regional clinical trials in Asia Pacific. At Antengene, we focus on developing drug candidates with novel MoAs and first-in-class/best-in-class potential to address significant unmet medical needs. The vision of Antengene is to “Treat Patients Beyond Borders” through research, development and commercialization of first-in-class/best-in-class therapeutics.
The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.